- Home
- LQDA vs GTX Comparison
LQDA vs GTX Comparison
Compare LQDA & GTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LQDA | GTX |
|---|---|---|
| Founded | 2004 | 2018 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.5B |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | LQDA | GTX |
|---|---|---|
| Price | $42.70 | $19.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 4 |
| Target Price | ★ $38.60 | $20.00 |
| AVG Volume (30 Days) | 2.3M | ★ 2.4M |
| Earning Date | 03-18-2026 | 02-19-2026 |
| Dividend Yield | N/A | ★ 1.67% |
| EPS Growth | N/A | ★ 55.30 |
| EPS | N/A | ★ 1.57 |
| Revenue | $69,216,000.00 | ★ $3,537,000,000.00 |
| Revenue This Year | $993.31 | $3.71 |
| Revenue Next Year | $219.14 | $3.41 |
| P/E Ratio | ★ N/A | $12.21 |
| Revenue Growth | ★ 343.41 | N/A |
| 52 Week Low | $11.26 | $7.02 |
| 52 Week High | $46.67 | $19.28 |
Technical Indicators
Market Signals| Indicator | LQDA | GTX |
|---|---|---|
| Relative Strength Index (RSI) | 59.86 | 56.60 |
| Support Level | $41.34 | $18.14 |
| Resistance Level | $46.67 | $18.67 |
| Average True Range (ATR) | 2.51 | 0.48 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 63.78 | 79.02 |
Price Performance
Historical ComparisonAbout LQDA Liquidia Corporation
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
About GTX Garrett Motion Inc.
Garrett Motion Inc designs, manufactures and sells engineered turbocharger and electric-boosting technologies for light and commercial vehicle original equipment manufacturers (OEMs). The company is a technology leader with expertise in delivering products across gasoline, diesel, natural gas and electrified powertrains. The company also sells its technologies in the aftermarket through its distribution network. The company derives maximum of its revenue from Gas and geographically from Europe.